An Iranian nano-pharmaceutical would hit the market by March 2012. The drug is the Middle East's first non-carcinogenic nanomedicine which should be used through injection. Iran will break the US monopoly for the similar medicine after 13 years.
Iranian researchers managed to produce and unveil the new type of antibiotic which is used in various types of abdominal cancers trade named "SinaDoxosome" with similar application to Doxorubicin known by trade name of Doxil which is in the US monopoly for 13 years and is sold for a great fortune.
Doxorubicin is used for cancer chemotherapy. It is an anthracycline antibiotic, closely related to the natural product daunomycin, and like all anthracyclines, it works by intercalating DNA.
Doxorubicin is commonly used in the treatment of a wide range of cancers, including hematological malignancies, many types of carcinoma, and soft tissue sarcomas.
The locally made nano-medicine connects doxil to DNA and prevents the formation of nucleic acid. Studies show that doxil can rapidly diffuse into the cell and stick to chromatin around the nuclei. They also show that this medicine can quickly avoid cancerous cells.
This nanomedicine is 100 nanometers in diameter.
The tiny dimension of this drug makes possible its diffusion into the venous tissue of tumors, and it can carry a considerable amount of medicine.
Among the advantages of this drug over the similar non-anemometric medicines, mention can be made of higher solubility, lower toxicity, longer period of staying in the target cell, and more easily diffusion into the cell.
Related Site: Iran Nano 2011
... Payvand News - 10/11/11 ... --